• Explore /
  • Poster
  • / First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.

First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.

Abstract Poster

Authors

null

Ning Li

Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Ning Li , Jifang Gong , Jian Zhang , Dan Liu , Yaqing Chen , Youzhong Zhang , Yi Huang , Jing Wang , Jie Tang , Guiling Li , Ying Wang , Junyan Wu , Suxia Luo , Ge Lou , Wei Duan , Robert Huang , Mo Xu , Xichun Hu , Lingying Wu , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04740398

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 5556)

DOI

10.1200/JCO.2024.42.16_suppl.5556

Abstract #

5556

Poster Bd #

427

Abstract Disclosures

Similar Posters

First Author: Jifang Gong

First Author: Junning Cao

First Author: Alexander I. Spira

First Author: Caicun Zhou